Core Viewpoint - The company, Haixi New Drug, is planning a global offering of 11.5 million H-shares, with a price range of HKD 69.88 to HKD 86.40 per share, aiming to raise approximately HKD 848 million for various purposes including R&D and commercialization [1][4]. Group 1: Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company with integrated R&D, manufacturing, and sales capabilities, focusing on a diverse product portfolio in the fastest-growing therapeutic areas in China [2]. - The company has a product portfolio that includes generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, which collectively account for over 25% of China's pharmaceutical sales in 2023 [2][3]. Group 2: Product Pipeline and Approvals - As of the latest feasible date, the company has received approval for 15 generic drugs from the National Medical Products Administration and has established a pipeline of four innovative drugs [3]. - The innovative drug pipeline includes an oral drug for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, along with two other drugs in preclinical stages targeting tumors and respiratory diseases [2]. Group 3: Financial Aspects and Use of Proceeds - The cornerstone investor, Harvest Oriental SP, has agreed to subscribe for approximately USD 22 million worth of shares at a median indicative price of HKD 78.14 per share, totaling 219,120 shares [3]. - The estimated net proceeds of approximately HKD 848 million from the global offering will be allocated as follows: 52% for ongoing R&D investments, 23% for enhancing R&D capabilities and seeking collaborations, 8% for improving commercialization capabilities, 7% for optimizing R&D and production systems, and 10% for working capital and general corporate purposes [4].

公司已连续多年在ASH、美国临床肿瘤学会(ASCO)等国际舞台上发表创新药研发成果。此次多项研究 成果集中入选第67届ASH年会，代表了国际学术界对公司科研创新实力的高度认可。 智通财经APP讯，维立志博-B(09887)发布公告，美国血液学会(ASH)公布了第67届年会摘要评审结果。 公司2款创新药共5篇研究摘要成功入选，包括1篇口头报告、3篇壁报展示和1篇在线发表。 （原标题：维立志博-B(09887)：2款创新药研究成果将亮相第67届ASH年会） ...

公司已连续多年在ASH、美国临床肿瘤学会(ASCO)等国际舞台上发表创新药研发成果。此次多项研究 成果集中入选第67届ASH年会，代表了国际学术界对公司科研创新实力的高度认可。 维立志博-B(09887)发布公告，美国血液学会(ASH)公布了第67届年会摘要评审结果。公司2款创新药共5 篇研究摘要成功入选，包括1篇口头报告、3篇壁报展示和1篇在线发表。 ...

（股 份 代 號：9887） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 2款創新藥研究成果將亮相第67屆ASH年 會 本公告由南京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） 本 公 司 股 東 及 潛 在 投 資 者 在 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承董事會命 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 董 事 長、執 行 董 事 兼 首 席 ...

广州必贝特医药股份有限公司 深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 首次公开发行股票并在科创板上市 招股意向书附录 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1-40 | | 2 | 财务报表及审计报告 | 41-211 | | 3 | 内部控制审计报告 | 212-220 | | 4 | 经注册会计师核验的非经常性损益明细表 | 221-230 | | 5 | 法律意见书 | 231-587 | | 6 | 律师工作报告 | 588-809 | | 7 | 发行人公司章程（草案） | 810-861 | | 8 | 中国证监会同意本次发行注册的文件 | 862-863 | 中信证券股份有限公司 关于 广州必贝特医药股份有限公司 首次公开发行股票并在科创板上市之 发行保荐书 保荐人（主承销商） | 目 录 1 | | --- | | 声 明 2 | | 第一节 本次证券发行基本情况 3 | | 一、保荐人名称 3 | | 二、保荐代表人、项目协办人及其它项目组成员情况 3 | | 三、发行人基本情况 4 | | 四、本次推荐发行 ...

投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 广州必贝特医药股份有限公司 BeBetter Med Inc. （广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第八层 802 房） 首次公开发行股票并在科创板上市 招股意向书 （深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层） 本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创板公司具有研发 保荐人（主承销商） 广州必贝特医药股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资 ...

Core Points - The company, Bibet (688759.SH), has released its prospectus for an initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 90 million shares, which will account for approximately 20.00% of the total share capital post-issuance [1] - The IPO will consist entirely of new shares, with no existing shareholders selling shares [1] - The initial strategic placement will involve 18 million shares, representing 20.00% of the total issuance, with final placement amounts to be determined after the pricing on October 15, 2025 [1] Company Overview - Bibet is a biopharmaceutical company focused on innovative drug development, particularly in the fields of oncology, autoimmune diseases, and metabolic diseases [1] - The company aims to develop First-in-Class drugs and innovative medications to meet unmet clinical needs, emphasizing independent innovation and global intellectual property rights [1] Research Pipeline - As of the signing date of the prospectus, the company has one Class 1 innovative drug, BEBT-908, approved for market, while BEBT-209 is in Phase III clinical trials, and BEBT-109 has been approved to start Phase III trials [2] - Five additional products are currently in Phase I clinical trials [2] Fund Utilization - The net proceeds from the IPO, after deducting issuance costs, will be allocated as follows: 949 million yuan for new drug research and development projects, 555 million yuan for the construction of a research and development center and formulation industrialization base in Qingyuan, and 500 million yuan for working capital [2]

Group 1 - The core point of the news is that Bibet (688759.SH) has released its IPO prospectus for listing on the Sci-Tech Innovation Board, planning to issue 90 million shares, which will account for approximately 20.00% of the total share capital post-issuance [1] - The initial strategic placement will involve 18 million shares, representing 20.00% of the total issuance, with the final strategic placement amount to be determined after the pricing on October 15, 2025 [1] - Bibet focuses on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to creating First-in-Class drugs and addressing unmet clinical needs [1] Group 2 - As of the signing date of the prospectus, the company has one Class 1 innovative drug, BEBT-908, approved for market, while BEBT-209 is in Phase III clinical trials, and BEBT-109 has been approved to start Phase III trials, with five products in Phase I trials [2] - The net proceeds from the IPO, after deducting issuance costs, will be allocated to various projects: 949 million yuan for new drug research and development, 555 million yuan for the construction of the Qingyuan R&D center and formulation industrialization base, and 500 million yuan for working capital [2]

Core Viewpoint - The article highlights the explosive performance of Changfeng Pharmaceutical upon its debut on the Hong Kong stock market, with a significant price increase and strong interest in the biotechnology sector despite a generally weak market [1][3][6]. Company Performance - Changfeng Pharmaceutical was listed on October 8, opening at 47 HKD per share and reaching a peak of 48.8 HKD, representing a rise of over 230% from its issue price of 14.75 HKD [1][3]. - The stock's first-day performance allowed investors to potentially earn over 17,000 HKD per lot (500 shares) if transaction fees are excluded [1]. - The company specializes in the research, development, production, and commercialization of inhalation technologies and drugs, focusing on respiratory diseases [4]. Financial Performance - The revenue figures for Changfeng Pharmaceutical over the years are as follows: 2022 - 349 million CNY, 2023 - 556 million CNY, 2024 - 608 million CNY, and Q1 2025 - 136 million CNY. The gross profits for the same periods were 268 million CNY, 458 million CNY, 491 million CNY, and 108 million CNY respectively [5]. Market Context - The biotechnology sector saw a collective rise of nearly 1% in the Hong Kong market, with several companies like Yiming Anke, He Yu, and others experiencing significant gains [2][6]. - Analysts suggest that the surge in biotechnology stocks may be linked to the announcement of the 2025 Nobel Prize in Physiology or Medicine, which recognized contributions to peripheral immune tolerance research [7][8]. Product Highlights - CF017, an inhalation drug for bronchial asthma, is Changfeng Pharmaceutical's first approved product, capturing approximately 16% of the Chinese market for budesonide inhalation drugs by sales volume in 2024 [5].

Core Insights - The acute gout medication market in China is projected to reach $100 million in 2024, contrasting sharply with the growing patient base of 19.4 million, which has increased by over 70% since 2019 [1][17] - The global acute gout medication market has seen a slight decline from $1.6 billion in 2019 to $1.5 billion in 2024, primarily due to rising prices of traditional drugs and their limitations, but is expected to rebound to $3.3 billion by 2030 with the introduction of new innovative treatments [13][14] Industry Overview - Acute gout medications are designed to quickly alleviate inflammation symptoms during acute attacks, focusing on suppressing inflammation rather than directly lowering uric acid levels [1][6] - The industry supply chain consists of upstream raw material suppliers, midstream manufacturers, and downstream distributors, with each segment's performance affecting the others [8][9] Market Dynamics - The global number of acute gout patients is expected to rise from 35.2 million in 2019 to 45.4 million in 2024, with a compound annual growth rate of 5.3%, driven by factors such as aging populations and dietary changes [11] - The current market is dominated by traditional drugs like allopurinol and febuxostat, which face challenges due to their toxicity, prompting a shift towards innovative drug development [17] Competitive Landscape - The acute gout medication market is characterized by a tiered competition structure, with major international players like Pfizer and Amgen leading the first tier, while domestic companies like Hengrui Medicine are emerging in the third tier with significant market shares [2][11] - The competition is shifting from price wars over traditional drugs to innovation-focused strategies, as companies invest in new drug development targeting specific mechanisms [2][11] Research and Analysis - The research team employs various analytical models such as SCP, SWOT, and PEST to comprehensively assess the market environment, industry policies, and competitive landscape [2][4] - A detailed report titled "2025-2031 China Acute Gout Medication Industry Market Research and Development Trend Forecast" has been compiled to guide investment decisions and strategic planning for stakeholders [23]